Financial Summary (All financials)
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
Revenues | 4,110.0 | 4,234.0 | 2,940.0 | 12,127.0 | 13,729.0 | 12,728.0 | 11,271.0 | 11,688.0 |
Revenue growth | -2.9% | 44.0% | -75.8% | -11.7% | 7.9% | 12.9% | -3.6% | -19.9% |
Cost of goods sold | 301.0 | 2,885.0 | 2,394.0 | 6,476.0 | 7,215.0 | 6,635.0 | 6,232.0 | 5,779.0 |
Gross profit | 3,809.0 | 1,349.0 | 546.0 | 5,651.0 | 6,514.0 | 6,093.0 | 5,039.0 | 5,909.0 |
Gross margin | 92.7% | 31.9% | 18.6% | 46.6% | 47.4% | 47.9% | 44.7% | 50.6% |
Selling, general and administrative | 1,058.0 | 831.0 | 798.0 | 1,118.0 | 1,483.0 | 1,417.0 | 1,287.0 | 1,267.0 |
Research and development | | 109.0 | 18.0 | 24.0 | 12.0 | 13.0 | 9.0 | 10.0 |
EBITA | -783.0 | -633.0 | -1,269.0 | 3,472.0 | 3,918.0 | 3,500.0 | 2,517.0 | 2,855.0 |
EBITA margin | -19.1% | -15.0% | -43.2% | 28.6% | 28.5% | 27.5% | 22.3% | 24.4% |
Amortization of intangibles | | 18.0 | 17.0 | 17.0 | 16.0 | 16.0 | 15.0 | 14.0 |
EBIT | -783.0 | -651.0 | -1,286.0 | 3,455.0 | 3,902.0 | 3,484.0 | 2,502.0 | 2,841.0 |
EBIT margin | -19.1% | -15.4% | -43.7% | 28.5% | 28.4% | 27.4% | 22.2% | 24.3% |
Pre-tax income | -1,387.0 | -1,474.0 | -1,876.0 | 3,600.0 | 3,326.0 | 3,054.0 | 2,264.0 | 2,622.0 |
Income taxes | 154.0 | -5.0 | 24.0 | 432.0 | 375.0 | -209.0 | 239.0 | 236.0 |
Tax rate | | 0.3% | | 12.0% | 11.3% | | 10.6% | 9.0% |
Earnings from continuing ops | -1,075.0 | -2,623.0 | -1,442.0 | 2,562.0 | 2,413.0 | 2,808.0 | 1,679.0 | 1,966.0 |
Earnings from discontinued ops | 2,907.0 | 193.0 | -243.0 | 136.0 | | | | |
Net income | 1,832.0 | -2,430.0 | -1,685.0 | 2,698.0 | 2,413.0 | 2,808.0 | 1,679.0 | 1,966.0 |
Net margin | 44.6% | -57.4% | -57.3% | 22.2% | 17.6% | 22.1% | 14.9% | 16.8% |
|
Diluted EPS | ($1.41) | ($3.43) | ($1.89) | $3.32 | $3.07 | $3.55 | $2.11 | $2.46 |
Shares outstanding (diluted) | 764.0 | 764.0 | 764.0 | 771.0 | 786.0 | 792.0 | 795.0 | 798.0 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|